Roche Defends Accutane Against New Evidence In NJ Retrial

Law360, New York (March 7, 2014, 8:57 PM EST) -- Hoffman-LaRoche Inc. on Friday urged a New Jersey jury to reject claims its drug Accutane causes inflammatory bowel disease, summating a case that was buttressed by new scientific evidence following an appellate reversal of a $10 million verdict awarded to the plaintiff in 2008.

Orlando R. Richmond of Butler Snow LLP, an attorney for Roche, told a New Jersey state jury that the evidence it heard in more than a month of testimony does not establish a causal connection between Roche’s Accutane and the ulcerative colitis suffered by the plaintiff, Kamie Kendall Rees, who took Accutane to cure her severe recalcitrant...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!